ISSN: 1308-5727 | E-ISSN: 1308-5735
Volume: 16 Issue: 1 Year: 2024
Forms

Abstracting & Indexing
Turkish Society for Pediatric Endocrinology and Diabetes
A Child with Prostaglandin I2-associated Thyrotoxicosis: Case Report [J Clin Res Pediatr Endocrinol]
J Clin Res Pediatr Endocrinol. 2019; 11(2): 207-210 | DOI: 10.4274/jcrpe.galenos.2018.2018.0169

A Child with Prostaglandin I2-associated Thyrotoxicosis: Case Report

Yuri Sonoda1, Kenichiro Yamamura1, Kanako Ishii1, Kazuhiro Ohkubo1, Kenji Ihara2, Yasunari Sakai1, Shouichi Ohga1
1Kyushu University Graduate School of Medical Sciences, Department of Pediatrics, Fukuoka, Japan
2Van Yüzüncü Yıl University Faculty of Medicine, Department of Pediatrics, Division of Neonatology, Van, Turkey

Prostaglandin I2 (PGI2) causes hyperthyroidism, a critical complication in patients with pulmonary arterial hypertension (PAH). However, it remains unknown whether PGI2 may have unfavorable effects on thyroid function in children with congenital portosystemic venous shunt syndrome (CPSVS). We present a boy with CPSVS who developed PAH at seven years of age. During ongoing PGI2 therapy, he experienced thyrotoxicosis at 17 years of age. The literature review showed that the reported 12 patients with PAH (median 11 years of age) developed hyperthyroidism during between one and 11 years of PGI2 treatment. Only one patient survived the acute PAH crisis due to hyperthyroidism. These data provide evidence that prophylactic intervention for hyperthyroidism is indicated for children with CPSVS during PGI2 treatment.

Keywords: Prostaglandin I2, pulmonary arterial hypertension, congenital portosystemic venous shunt syndrome, hyperthyroidism

Yuri Sonoda, Kenichiro Yamamura, Kanako Ishii, Kazuhiro Ohkubo, Kenji Ihara, Yasunari Sakai, Shouichi Ohga. A Child with Prostaglandin I2-associated Thyrotoxicosis: Case Report. J Clin Res Pediatr Endocrinol. 2019; 11(2): 207-210
Manuscript Language: English
LookUs & Online Makale